Cytotoxic activity of p58+ cytotoxic T lymphocyte clone 4C7 against autologous normal targets and allogeneic tumor cell lines
| . | . | Medium . | Anti-p58.2 . | AntiHLA- B/C . | Ctrl mAb . |
|---|---|---|---|---|---|
| Cell line/HLA | Origin | Percentage of lysis at 5/1 | |||
| DM/HLA-A1, A2 | Auto RCC | 4 | 26 | 24 | 5 |
| DM/HLA-A1, A2 | Auto PHA-b | 1 | 1 | 0 | 1 |
| DM/HLA-A1, A2 | Auto EBV B | 0 | 0 | 0 | 0 |
| LM/HLA-A1, A19 | Allo RCC | 9.6 | 33 | 26.5 | 10 |
| LM/HLA-A1, A19 | Allo NRC | 1 | 20 | 24 | 0 |
| MT/HLA-A1, A29 | Allo RCC | 12.5 | 23 | 32 | 9 |
| GF/HLA-A1, A29 | Allo RCC | 37 | 62 | 56 | 38 |
| VM/HLA-A2, A26 | Allo RCC | 6.6 | 7.5 | ND | 7 |
| LR/HLA-A2, A29 | Allo RCC | 5.6 | 9 | ND | 6.5 |
| . | . | Medium . | Anti-p58.2 . | AntiHLA- B/C . | Ctrl mAb . |
|---|---|---|---|---|---|
| Cell line/HLA | Origin | Percentage of lysis at 5/1 | |||
| DM/HLA-A1, A2 | Auto RCC | 4 | 26 | 24 | 5 |
| DM/HLA-A1, A2 | Auto PHA-b | 1 | 1 | 0 | 1 |
| DM/HLA-A1, A2 | Auto EBV B | 0 | 0 | 0 | 0 |
| LM/HLA-A1, A19 | Allo RCC | 9.6 | 33 | 26.5 | 10 |
| LM/HLA-A1, A19 | Allo NRC | 1 | 20 | 24 | 0 |
| MT/HLA-A1, A29 | Allo RCC | 12.5 | 23 | 32 | 9 |
| GF/HLA-A1, A29 | Allo RCC | 37 | 62 | 56 | 38 |
| VM/HLA-A2, A26 | Allo RCC | 6.6 | 7.5 | ND | 7 |
| LR/HLA-A2, A29 | Allo RCC | 5.6 | 9 | ND | 6.5 |
Lysis of renal tumor cells was tested after preincubation with monoclonal antibodies (mAbs) of effector cells (anti-p58.2) or of tumor target cells (anti-HLA-B/C). The control was lysis of targets tested after no preincubation (medium) and after preincubation of targets with HLA-DR mAb (Ctrl mAb). Results are expressed as the percentage of lysis in a 4-hour chromium 51-release assay. Values in boldface represent significantly increased lysis in the presence of mAbs. RCC indicates renal cell carcinoma; PHA-b, phytohemagglutinin-blasts; EBV B, Epstein-Barr virus-transformed B cells; NRC, normal renal cells; and ND, not done.